by Clinical Neuropsychologist Online | Wednesday, October 23, 2024 | Dementia
Abstract INTRODUCTION Assessing treatments for Alzheimer’s disease (AD) relies on reliable tools for measuring AD progression. In this analysis, we evaluate the sensitivity of clinical progression measures in AD within randomized controlled trials (RCTs) with...
by Clinical Neuropsychologist Online | Wednesday, October 23, 2024 | Dementia
Abstract BACKGROUND Metabolic dysregulation is a hallmark of neurodegenerative diseases, including Alzheimer’s disease (AD) and progressive supranuclear palsy (PSP). Although metabolic dysregulation is a common link between these two tauopathies, a comprehensive...
by Clinical Neuropsychologist Online | Monday, October 21, 2024 | Dementia
Abstract On the 20th anniversary of the Alzheimer’s Disease Neuroimaging Initiative (ADNI), this paper provides a comprehensive overview of the role of arterial spin labeling (ASL) magnetic resonance imaging (MRI) in understanding perfusion changes in the aging...
by Clinical Neuropsychologist Online | Monday, October 21, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s Disease Neuroimaging Initiative (ADNI) has been pivotal in identifying and refining Alzheimer’s disease (AD) biomarkers for clinical trials. This study leverages longitudinal data from participants who have progressed to...
by Clinical Neuropsychologist Online | Monday, October 21, 2024 | Dementia
Abstract INTRODUCTION Evaluating the generalizability of dementia risk scores, primarily developed in non-Latinx White (NLW) participants, and interactions with genetic risk factors in diverse populations is crucial for addressing health disparities. METHODS We...
